Skip to main content
MedPathMedPath Home
Clinical Trials/NCT07275840
NCT07275840
Recruiting
Phase 2

An Open-label, Multicenter, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Intravitreal Injection of IBI302 in Participants With Neovascular Age-related Macular Degeneration

Innovent Biologics Technology Limited (Shanghai R&D Center)2 sites in 1 country800 target enrollmentStarted: December 5, 2025Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
InterventionsIBI302 8mg dose

Overview

Phase
Phase 2
Status
Recruiting
Sponsor
Innovent Biologics Technology Limited (Shanghai R&D Center)
Enrollment
800
Locations
2
Primary Endpoint
Proportion of participants whose best corrected visual acuity (BCVA) of the study eye decreased by less than 15 letters from baseline as measured by the visual acuity chart in the early treatment diabetic retinopathy study (ETDRS) at week 52
OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Overview

Brief Summary

This study is designed for Open-label, multi-center, single-arm Phase II trail to evaluate the efficacy and safety of intravitreal injection of IBI302 in nAMD patients.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
50 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Have signed an informed consent form before participating in the research.
  • •Male or female individuals aged 50 or above at the time of signing the informed consent form;
  • •Active CNV under the macular fovea secondary to nAMD or active CNV involving the macular fovea.
  • •At baseline, the BCVA of the study eye was within the range of 19 to 78 ETDRS letters (including both ends).

Exclusion Criteria

  • •According to the investigator's judgment, concomitant ocular diseases/systemic diseases of the study eyes at screening or baseline may lead to participants' non-response to the study treatment or confuse the interpretation of the study results;
  • •The study eye has uncontrollable glaucoma;
  • •There is an active intraocular or periocular infection or inflammation in either eye;
  • •The non-study eye has severe visual function disorders;
  • •Within 90 days before baseline, the study eye had received anti-VEGF treatment;
  • •Within 90 days before baseline, the study eye had received anti-complement treatment;
  • •At any time before baseline, the study eye had received IBI302 treatment;
  • •Uncontrollable hypertension;
  • •Glycated hemoglobin (HbA1c) \> 10.0% within 28 days prior to screening;
  • •Other exclusion criteria set by protocol.

Arms & Interventions

IBI302 8mg dose 8mg

Experimental

Drug: IBI302 8mg/Intravitreal injection

Intervention: IBI302 8mg dose (Drug)

Outcomes

Primary Outcomes

Proportion of participants whose best corrected visual acuity (BCVA) of the study eye decreased by less than 15 letters from baseline as measured by the visual acuity chart in the early treatment diabetic retinopathy study (ETDRS) at week 52

Time Frame: Week52

Secondary Outcomes

  • The changes in BCVA from baseline at each visit(Baseline，Weeks 4，8，12，16，20，24，28，32，36，40，44，48 and 52)
  • Proportion of patients with BCVA improvement of ≥0, ≥5, ≥10, and ≥15 ETDRS letters from baseline at week 52(Week52)
  • Proportion of participants with a decrease in BCVA of >0, ≥5, ≥10, and ≥15 ETDRS letters from baseline at week 52(Week52)
  • The change in central subfield thickness of the macula measured by OCT from the baseline at week 52(Week52)
  • Proportion of participants with IRF/SRF/Pigment epithelial detachment (PED) on OCT at Week 52(Week52)
  • Change in choroidal neovascularization (CNV) area on fundus fluorescein angiography (FFA) at week 52 compared to baseline(Week52)
  • Change in CNV leakage area on FFA at week 52 compared to baseline(Week52)
  • Proportion of participants with new-onset MA on OCT at Week 52(Week52)
  • Proportion of new-onset fibrosis on color fundus photography (CFP) at Week 52(Week52)
  • Change in MA area on OCT from baseline at Week 52(Week52)
  • Change in fibrosis area and maximum lesion diameter on CFP from baseline at Week 52(Week52)
  • The incidence rate, correlation with the studied drugs, and severity of ocular and systemic adverse events (AE), treatment emergent adverse events (TEAE), and serious adverse events (SAE)(From baseline through Week 52)
  • The production of anti-drug antibodies in the serum(Day0、Week4、Week16、Week32、Week48、Week52)

Investigators

Sponsor
Innovent Biologics Technology Limited (Shanghai R&D Center)
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials

Recruiting
Phase 2
A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics
NCT07260500Changchun GeneScience Pharmaceutical Co., Ltd.72
Recruiting
Phase 1
BY002 IIT Study in R/R Acute Leukemia
NCT07270770The First Affiliated Hospital of Soochow University18
Not yet recruiting
Not Applicable
CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer
NCT07268794Fudan University112
Not yet recruiting
Not Applicable
Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHN
NCT07264075Groupe Oncologie Radiotherapie Tete et Cou780
Not yet recruiting
Not Applicable
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
NCT07265258Innovent Biologics (Suzhou) Co. Ltd.92